We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Longtimeinvestor who wrote (52178)8/21/2019 6:04:31 PM
From: idahoranch12 Recommendations

Recommended By

  Respond to of 59231
I think the last two days are likely the CRL SRPT got from FDA. It was unexpected and at least to me, the reasons seem confusing. There is less confidence in FDA acting rationally by investors than two days ago.

Of course I’ve been on the “not trusting” side for a while now. Logically, our approval should be based on the companies manufacturing facility inspection which I expect has been brought up to and exceeding all that FDA has asked.

The question is, like us the first time around, and SRPT yesterday, is FDA withholding communications on important items from the company that they will then use to issue a CRL? I really don’t think so, but the selling suggests there’s more of a concern since SRPT’s CRL than there was before.

To: Longtimeinvestor who wrote (52178)8/21/2019 6:07:37 PM
From: JohnBeach1 Recommendation

Recommended By

  Read Replies (1) | Respond to of 59231
World Lung website says full abstracts release today at 5 pm ET. According to the Daiichi PR it's
Abstract #3854. i can't find the abstract release though.